German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.
The partnership leverages IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic development.
These...
Global healthcare company AmerisourceBergen has announced a strategic partnership with business-to-business telehealth provider SteadyMD, beginning with the companies cocreating and piloting a telehealth offering for independent community pharmacies dubbed Test to Treat.
The Test to Treat model allows individuals to be tested for an illness or condition at an independent pharmacy and then consult...
Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.
The deal will net Click up to $460 million, plus tiered royalties. It builds on an earlier collaboration announced in 2020 that developed CT-155, an initial therapeutic for schizophrenia.
The companies...
This morning prescription digital therapeutic company Click Therapeutic announced a $52 million Series B funding round. H.I.G. BioHealth Partners and Accelmed Partners ll led the round, with participation from Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures and RdigetopHealth.
This news comes over a year after the company inked a $500 million-plus deal with...
It’s no secret that Click Therapeutics is on a roll with pharma partnerships. The mental health-focused digital therapeutic company made headlines this week when it announced a new clinical trial with Japanese pharma company Otsuka, based on a deal made in 2019.
But this isn't the only deal the New York-based company worked on with the life science industry. In September, the company signed a $...
Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.
In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from...
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia.
The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said.
Employing cognitive and neurobehavioral...
This week saw the kickoff of HIMSS19, and the MobiHealthNews staff was on site to interview industry leaders and catch the latest insights from a range of health and tech experts. While the majority of MobiHealthNews' stories and videos from the show floor can be found on our HIMSS19 conference coverage page, there was no shortage of digital product launches, deals and other announcement ...
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.
Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they're prescribed the drug.
"Pradaxa is not different than any other...
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Launched in 2016, the web- and mobile-based RespiPoints program offers patients a variety of adherence-...
_1e92b.jpg "A woman holding a smartphone looking out a window.")
_43ae6.jpg)
